Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Alendronate and Risedronate

Abstract

Spanish

French

Background:

Bisphosphonate (BP)-related gastrointestinal (Gl) adverse events can lead to discontinuation of osteoporosis treatment. Irritation of the GI tract related to BPs may be worsened by more frequent administration.

Objective:

To compare the number of women who experienced severe GI events within 3 months of starling once-monthly oral ibandronate with those starting once-weekly oral BP (alendronate or risedronate).

Methods:

In a retrospective database study design, eligible women with a new prescription for monthly ibandronate were propensity-matched to women with a new weekly BP prescription. Patients had continuous health plan enrollment for 6 months prior to the index date and for 3 months after the index date. Women with previous intravenous BP treatment, Paget's disease, or oral BP treatment within the 6-month preindex period were excluded. Severe GI events (including acute events involving perforation or bleeding/perforation) within 3 months of treatment initiation were identified by ICD-9 and Current Procedural Terminology codes. A post hoc analysis assessed treatment discontinuation after severe GI events. GI-related healthcare utilization rates and costs were also compared,

Results:

Of the 8608 patients per group, 45 (0.52%) who were receiving monthly ibandronate and 70 (0.81%) of those receiving weekly BP treatment experienced a severe GI event. Ibandronate patients had a 36% reduction in the risk of severe GI events compared with weekly BP users (OR 0.64, 95% CI 0.44 to 0.93). Significantly more women receiving a weekly BP discontinued treatment after a severe GI event compared with those receiving ibandronate (100% vs 55.6%: p< 0.001). Most healthcare utilization outcomes were not significantly different between the 2 groups; outpatient visits were significantly higher for ibandronate (p = 0.02). Costs were not significantly different between the 2 groups.

Conclusions:

Patients receiving monthly ibandronate therapy had a significantly reduced risk of severe GI events compared with those receiving weekly BP treatment. In addition, patients receiving a weekly BP were more likely to discontinue treatment after a severe GI event.

Keywords

adverse event alendronate bisphosphonate gastrointestinal event ibandronate risedronate

Get full access to this article

View all access options for this article.

References

Eisman

Rizzoli

Roman-Ivorra

. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2004;20:699–705.

Reginster

Minne

Sorensen

. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91.

Taggart

Bolognese

Lindsay

. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Prac 2002;77:262–70.

Siris

Harris

Rosen

. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22.

Hamilton

McCoy

Taggart

. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259–62.

Penning-van Beest

Goettsch

Erkens

Herings

. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236–42.

Tosteson

Grove

Hammond

. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209–16.

Lanza

. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treat Endocrinol 2002;1 37–43.

Cryer

Bauer

. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031–43.

10.

Product information. Boniva (ibandronate sodium). Nutley, NJ: Roche Laboratories Inc., August 2006.

11.

Lewiecki

Babbitt

Piziak

Ozturk

Bone

. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008; 30: 605–21.

12.

Binkley

Martens

Silverman

. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. South Med J, in press.

13.

Emkey

Koltun

Beusterien

. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–903.

14.

Koltun

Emkey

Kroll

Kohles

. Monthly ibandronate is more tolerable than weekly alendronate: results of BALTO I and II studies (abstract). Obstet Gynecol 2007;4: 98S.

15.

Graham

. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002;47:1665–78.

16.

Miller

Bolognese

Worley

Solis

Sheer

. Incidence of gastrointestinal events among bisphosphonate patients in an observational setting. Am J Manag Care 2004;10(suppl):S207–15.

17.

Kurth

Walker

Glynn

. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262–70.

18.

Rosen

Hochberg

Bonnick

. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141–51. Epub 29 Sept 2004.

19.

Ettinger

Pressman

Schein

. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377–82.

20.

Kane

Borisov

Brixner

. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Manag Care 2004;10(suppl):S216–26.

21.

Black

Thompson

Bauer

. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118–24.

22.

Cummings

Black

Thompson

. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82.

23.

Harris

Watts

Genant

. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52.

24.

McClung

Geusens

Miller

. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333–40.

25.

Black

Cummings

Karpf

. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41.

26.

Chesnut

Skag

Christiansen

. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9.

27.

Chesnut

Ettinger

Miller

. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21:391–401.

28.

Brown

Kendler

McClung

. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103–11.

29.

Delmas

McClung

Zanchetta

. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36–42.

30.

Schnitzer

Bone

Crepaldi

. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treat-ment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1–12.

31.

Miller

McClung

Macovei

. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315–22.

32.

Reginster

Adami

Lakatos

. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654–61.

33.

Cranney

Wells

Adachi

. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291–7. DOI 10.1007/s00198-008-0653-8

34.

Harris

Blumentals

Miller

. Ibandronate and the risk of nonvertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237–45.